Aurobindo Pharma shares traded 1% higher on Tuesday despite a slight dip in its fourth-quarter profits to ₹903 crore.

a wholly owned subsidiary of Aurobindo Pharma, and enter into a contract manufacturing relationship. In addition to the Houston facility, the site will serve as the second FDA-registered ...

The new site has been completed with an investment ... Muralidharan, President, European Operations at Aurobindo Pharma, said: "We are delighted to be reinforcing our commitment to the Auvergne ...

An FDA inspection of an Aurobindo Pharma manufacturing facility last fall ... Sandoz in the U.S. as well as three manufacturing sites. That deal was announced in 2018 but has been repeatedly ...

On Wednesday, Aurobindo Pharma Ltd. told the exchanges that its new injectable plant in Andhra Pradesh has acquired its first product approval from the USFDA. Eugia Steriles, a 100% subsidiary of ...

Aurobindo Pharma Ltd. is an integrated pharmaceutical company that delivers innovative solutions. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients.

Meanwhile, shares of Aurobindo Pharma hit the day's low following the news of the VAI classification. At 12.44 pm, shares of Aurobindo Pharma were trading one percent lower at Rs 1,185.75 on the NSE.

Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA ...

On Tuesday, Hyderabad-based medicine company Aurobindo Pharma Ltd. announced its first ever buyback of equity shares valued up to ₹750 Crore. Shares, however, have fallen since the news.